PHASE II CLINICAL TRIAL OF IMMUNOTHERAPY WITH AN ALLOGENEIC B7.1/HLA-A1 TRANSFECTED TUMOR CELL VACCINE (PT 107) IN PATIENTS WITH STAGES IIIB/IV NON-SMALL CELL LUNG CANCER THAT HAVE COMPLETED FIRST LINE CHEMOTHERAPY.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs PT 107 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Oct 2011 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India.
- 02 Dec 2010 New trial record